Evidence for a rapid inhibitor to tissue plasminogen activator in plasma.
about
The effect of dilution, pH and ionic strength of plasma on t-PA precipitation in euglobulin fractionExogenous estrogen may exacerbate thrombophilia, impair bone healing and contribute to development of chronic facial painHypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivoPlasminogen activator inhibitor (PAI-1) in plasma and platelets.Attenuation by prolonged nitric oxide synthase inhibition of the enhancement of fibrinolysis caused by environmental stress in the rat.Platelet protease nexin-1, a serpin that strongly influences fibrinolysis and thrombolysis.Possibilities of DNA analysis for the detection of predisposition to thrombotic disease.Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation.Inhibitors and activators of fibrinolysis during and after childbirth in maternal and cord blood.Plasminogen activation: biochemistry, physiology, and therapeutics.Tissue plasminogen activator: an evaluation of clinical efficacy in acute myocardial infarction.Differences in coagulation and fibrinolysis after traumatic and septic shock in man.Persimmon leaf flavonoid induces brain ischemic tolerance in mice.Production of lactate and tissue plasminogen activator in vitro by seminiferous tubules obtained from adult unilaterally cryptorchid rats.The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma.Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus.A randomized lifestyle intervention with 5-year follow-up in subjects with impaired glucose tolerance: pronounced short-term impact but long-term adherence problems.Plasminogen activator inhibitor-1 in obstructive sleep apnea patients with and without hypertension.Antiphospholipid antibodies: a new risk factor for restenosis after percutaneous transluminal coronary angioplasty?Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance.Elevation of plasminogen activator inhibitor 1 in borderline hypertension is linked to concomitant metabolic disturbances.Plasma fibrinogen in relation to serum insulin, smoking habits and adipose tissue fatty acids in healthy men.Coagulation and fibrinolysis during the normal menstrual cycle.Activation of cascade systems by hip arthroplasty. No difference between fixation with and without cement.Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeptide-p-nitroanilide substrates.The -675 4G/5G polymorphism at the Plasminogen Activator Inhibitor 1 (PAI-1) gene modulates plasma Plasminogen Activator Inhibitor 1 concentrations in response to dietary fat consumption
P2860
Q23915125-8722AC7B-FD46-4ABA-8B51-CA106D0B0541Q28291444-0FFA6ED6-E175-423E-9349-3FE03A8EC268Q28343977-44350226-A159-46D7-94CB-B832C6D47318Q33449201-D5BD7F96-2441-4335-A294-E36A98B2144CQ33497442-29995444-80C1-4BA8-97D3-15A06C6B81F6Q33845781-63F57B5A-0DC7-4553-A444-A280B4C68937Q35224536-39054BC5-6CE1-47AE-8336-67EAE549B831Q35252511-733A4C89-ECC2-45AF-BFD0-24C6670447F3Q38237307-4442CF45-1D67-44A3-B8EA-AC99C2442672Q39489577-57DCE324-6B61-4263-B0C1-51EE29211A0BQ39598690-F2596081-1D8A-47DF-B942-5CB2CF6FBDF6Q41310739-6ED7E6E9-E875-4C86-8123-9BF87E599703Q42155325-29969DF3-27FB-46CF-AD48-8A3DCC9DB45AQ42504444-A6988477-A2D0-4685-93F8-3ECEFCE57CE7Q44540651-23800A9C-8AED-4EAE-99F6-E39DA9D19327Q44835478-6CA6A41C-09AA-4D70-A227-4F14C076ED89Q45254462-13142C6C-85F5-4214-ADE8-4781D4C3F3DDQ46710321-D5A696DC-ECD2-4A6C-B0FB-362D8B9C5427Q48021542-E9E04893-5072-4942-A870-C947EFAE142DQ51561686-C106552B-337F-4B1A-8346-404CB7827028Q51580159-86EBECA0-668D-400E-B846-D90BA530C31DQ51596762-8EFB911F-88BD-4986-9007-7E66E0528133Q51623421-F5B0D8F3-A288-4E50-8414-9447BB2126DFQ51790347-46F40DCE-2B42-4791-9A5B-F76A835A7320Q53755999-C6233FB2-4DF4-44DC-8F30-1EDA2FA3912CQ57336887-6FE0072E-953F-442A-B253-DE43C396C503
P2860
Evidence for a rapid inhibitor to tissue plasminogen activator in plasma.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年学术文章
@wuu
1983年学术文章
@zh
1983年学术文章
@zh-cn
1983年学术文章
@zh-hans
1983年学术文章
@zh-my
1983年学术文章
@zh-sg
1983年學術文章
@yue
1983年學術文章
@zh-hant
name
Evidence for a rapid inhibitor to tissue plasminogen activator in plasma.
@en
Evidence for a rapid inhibitor to tissue plasminogen activator in plasma.
@nl
type
label
Evidence for a rapid inhibitor to tissue plasminogen activator in plasma.
@en
Evidence for a rapid inhibitor to tissue plasminogen activator in plasma.
@nl
prefLabel
Evidence for a rapid inhibitor to tissue plasminogen activator in plasma.
@en
Evidence for a rapid inhibitor to tissue plasminogen activator in plasma.
@nl
P2093
P1433
P1476
Evidence for a rapid inhibitor to tissue plasminogen activator in plasma.
@en
P2093
P304
P356
10.1016/0049-3848(83)90407-3
P577
1983-08-01T00:00:00Z